Olaparib

Olaparib is a PARP inhibitor that also acts on BRCA1 or BRCA2 mutations. Olaparib has little effect on anchor-1, and IC50 value is greater than that of OLaparib. The concentration of Olaparib at 30-100 nM acts on SW620 cells and inactivates PARP-1. Compared with BRCA1 and BRCA2-sufficient cell lines (Hs578T,MDA-MB-231,T47D), BRCA1-deficient cell lines (MDA-MB-463 [2] and HCC1937) were over-sensitive to Olaparib, which inhibited PARP and blocked base excisation repair. Resulting in strong sensitivity of KB2P cells to Olaparib. The result is a shift from a single strand break to a double strand break during DNA replication, thus activating the BRCA2-dependent recombination pathway.